In This Article:
We recently published a list of Here’s What Fueled These 10 Firms’ Surge. In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against other Tuesday’s best-performing stocks.
The stock market ended the trading session in the red on Tuesday, with all major indices giving up earlier gains, as investors sold off positions while waiting for the results of the Federal Reserve’s policy decision, while digesting President Donald Trump’s new tariff policies.
Among all the major indices, the Dow Jones fell the heaviest, down 0.95 percent. The tech-heavy Nasdaq followed with a 0.87-percent decline, while the S&P 500 finished with a 0.77-percent drop.
Beyond the major indices, 10 firms stood out with strong gains amid a flurry of fresh developments, including new partnerships, optimistic outlooks, and impressive earnings performance. In this article, we name Tuesday’s 10 best-performing stocks and detail the reasons behind their gains.
To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.
A healthcare professional discussing treatment options for a patient with a neurological disorder.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Neurocrine Biosciences extended its winning streak for a third day on Tuesday, adding 8.36 percent to finish at $118.92 apiece as optimistic outlooks from two investment firms buoyed investor sentiment.
On Tuesday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) received a “buy” recommendation from Needham & Company alongside a price target of $139, higher than the $138 as projected previously. The new price marked a 16.9-percent upside from its latest closing price.
According to Needham, its rating adjustment reflected its positive outlook for Ingrezza, the biopharmaceutical firm’s flagship product for the treatment of tardive dyskinesia.
In its latest earnings release, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) said that sales from Ingrezza exceeded expectations during the first quarter of the year, ending at $545 million versus the $525 million the company targeted earlier.
In another related development, BofA Securities also raised its price target to $183 from $179 previously and maintained its “buy” recommendation on the stock.
Overall, NBIX ranks 9th on our list of Tuesday’s best-performing stocks. While we acknowledge the potential of NBIX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NBIX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.